 multicenter clinical trial epoetin beta anemia end-stage renal disease Patients anemia end-stage renal disease weeks efficacy safety long-term benefits epoetin beta administration total patients double-blind placebo-controlled portion multicenter study first weeks fixed-dose period patients U/kg epoetin beta placebo thrice second weeks dose-adjustment period dose epoetin beta U/kg thrice patients placebo-controlled period open-label period patients active drug doses epoetin beta first weeks patients study phases study beta consistent sustained increase hemoglobin baseline g/dL hematocrit baseline need packed red blood cell transfusions Reticulocyte counts response beta levels baseline remainder study period baseline placebo group change parameters double-blind period Similar patterns response original placebo group crossover active drug mean hemoglobin increase